Braveheart Bio Q2 Results: EPS misses estimate, losses widen 1692%

0 min read | Published on 09 Sept 2026, 02:23 AM |Updated on 09 Sept 2026, 02:23 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

Braveheart Bio reported Q2 EPS of $(2.51)
Result missed analyst consensus estimate of $0.74 by 439.19%
Per-share losses widened 1,692.86% YoY from $(0.14)

*this image is generated using AI for illustrative purposes only.

Braveheart Bio (NASDAQ: BRVE) reported a quarterly loss of $(2.51) per share for the second quarter. The figure missed the analyst consensus estimate of $0.74 by 439.19 percent.

The per-share loss represents a significant deterioration compared to the prior year period.

What the Numbers Show

The widening loss reflects a sharp divergence from the previous year's performance. While the company reported a loss of $(0.14) per share in the same quarter last year, the current quarter's loss of $(2.51) marks a 1,692.86 percent increase in losses on a year-over-year basis. This magnitude of change indicates a substantial operational or financial shift during the period, moving the company further into negative territory despite the prior year's relatively contained loss position.

What specific operational or clinical factors drove the 1,692% year-over-year increase in per-share losses for Braveheart Bio?

How will this significant miss against analyst consensus impact the company's near-term cash runway and potential need for capital raising?

Are there upcoming catalysts, such as trial data releases or partnership announcements, that could offset investor concerns about the widening financial deficit?

Braveheart Bio to present at Cantor Global Healthcare Conference

0 min read | Published on 02 Sept 2026, 02:06 AM |Updated on 02 Sept 2026, 02:06 AM

Reviewed by

Anirudha BScanX News Team

Add as a preferred
source on Google

Key Highlights

Braveheart Bio to hold fireside chat on Sept 10, 2026
Event part of Cantor Global Healthcare Conference in New York
Lead candidate BHB-1893 targets obstructive and non-obstructive HCM
Live webcast available via company investor relations site

*this image is generated using AI for illustrative purposes only.

Braveheart Bio, Inc. (NASDAQ: BRVE) will participate in the Cantor Global Healthcare Conference next week. The clinical-stage biopharmaceutical company is scheduled for a fireside chat on Thursday, September 10, 2026, at 3:20 pm EDT in New York.

Management will discuss the company’s pipeline during the session. Interested parties can access a live webcast via the News & Events section of the Braveheart website. Replays will be available in a temporary archive following the event.

Pipeline Focus

Braveheart Bio focuses on developing therapies for patients with hypertrophic cardiomyopathy (HCM) and other serious cardiovascular diseases. Its lead product candidate, BHB-1893, is a next-generation oral small-molecule cardiac myosin inhibitor (CMI).

The company is developing BHB-1893 for the treatment of obstructive HCM (oHCM) and non-obstructive HCM (nHCM). Braveheart aims to address limitations of currently available CMIs by designing BHB-1893 for rapid onset and consistent depth of response.

Key design features include:

Preservation of systolic function
Prompt reversibility
Straightforward approach to titration and monitoring

Contact Information

Investor relations inquiries should be directed to Alexander Sharif at New Street Investor Relations. Media inquiries are handled by FGS Global.

What specific clinical trial milestones or data readouts for BHB-1893 are investors likely to anticipate from management during the fireside chat?

How does Braveheart Bio plan to differentiate BHB-1893's commercial strategy from existing cardiac myosin inhibitors like mavacamten in the hypertrophic cardiomyopathy market?

Will the company provide an updated timeline for regulatory submissions or potential partnerships regarding its lead candidate BHB-1893?